A phase II study of Sutent (SU11248) [sunitinib] as second line treatment in pleural mesothelioma after first line treatment with a platinum and antimetabolite

Trial Profile

A phase II study of Sutent (SU11248) [sunitinib] as second line treatment in pleural mesothelioma after first line treatment with a platinum and antimetabolite

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2008

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Mesothelioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top